Evidence map›Paper›PMID 32436167›Full record

ArticleScience and engineering ethics2020

Why Do Firms Implement Responsible Innovation? The Case of Emerging Technologies in South Korea.

Eunok Ko, Yeonbae Kim

Abstract read
PubMed Publisher
In one paragraph

Article in Science and engineering ethics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eunok KoKorea Evaluation Institute of Industrial Technology (KEIT), Cheomdan-Ro 8-Gil, Dong-Gu, Daegu, 701-300, Republic of Korea. eunriver@snu.ac.kr.ORCID http://orcid.org/0000-0003-4516-7501
Yeonbae KimTechnology Management, Economics and Policy Program (TEMEP), College of Engineering, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the rise of responsible innovation (RI) initiatives in firms that commercialize innovation in recent years, experts have argued that in order for RI to succeed, practical issues must be considered. Accordingly, this paper explores RI from the perspective of Korean emerging technology development firms. Although social benefits are expected from RI, which aims to reduce the side effects of innovations for society, the implementation of RI requires changing firms' existing rules and routines. Therefore, predicting benefits and costs from the firm's perspective can shed light on the likelihood that RI will succeed. In this study, through an expert survey, the relative weights of RI-related benefit criteria (technological level, economic performance, and public contribution) and cost criteria (anticipation, reflexivity, inclusion, and responsiveness) were analyzed. On this basis, trends in priorities for RI levels were evaluated from present and future perspectives. Unexpectedly, firms recognized that even if constraints such as RI impose greater costs, they will eventually bring greater benefits. This finding indicates that innovation induced by RI overcomes obstacles, offsets costs, and then finally increases firms' competitiveness, and that firms are willing to do good for society through RI. In the long term, a firm's ethical activities may eventually result in improved performance by its management. Therefore, it can be concluded that, even if RI is enforced in a compulsory manner, it is highly likely that it can be well established and promoted even in firms that consider profit first.

Indexed as

InventionsHumansRepublic of KoreaSocial ResponsibilityAnalytical hierarchy processCorporate social responsibilityEmerging technologyEthicsRegulationResponsible innovation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.